The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers.
 
Michael David Offin
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Megan Tenet
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Francisco Sanchez Vega
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Harpoon Therapeutics; Seagen
 
Gregory J. Riely
Consulting or Advisory Role - Genentech
Research Funding - ARIAD (Inst); GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Incyte; Lilly
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb